Citation of this article
Corresponding Author of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (2932)
All Articles published online
|
Sep 28, 2012 (publication date) through Apr 25, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Gastroenterology
ISSN
1007-9327
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: |
Lu C, Waugh A, Bailey RJ, Cherry R, Dieleman LA, Gramlich L, Matic K, Millan M, Kroeker KI, Sadowski D, Teshima CW, Todoruk D, Wong C, Wong K, Fedorak RN. Crohn’s disease genotypes of patients in remission |
|---|---|
| URL: | https://www.wjgnet.com/1007-9327/full/v18/i36/5058.htm |
| Number | Citing Articles |
| 1 |
Xiaolei Wang, Li Qin, Jingli Cao, Jing Zhao. Impact of NOD2/CARD15 polymorphisms on response to monoclonal antibody therapy in Crohn’s disease: a systematic review and meta-analysis. Current Medical Research and Opinion 2016; 32(12): 2007 doi: 10.1080/03007995.2016.1226168
|
| 2 |
T M Linares-Pineda, M Cañadas-Garre, A Sánchez-Pozo, M Á Calleja-Hernández. Pharmacogenetic biomarkers of response in Crohn’s disease. The Pharmacogenomics Journal 2018; 18(1): 1 doi: 10.1038/tpj.2017.27
|
| 3 |
Shomron Ben-Horin, Ren Mao, Yun Qiu, Minhu Chen. Discontinuation of Biological Treatments in Inflammatory Bowel Disease. Journal of Clinical Gastroenterology 2018; 52(1): 6 doi: 10.1097/MCG.0000000000000938
|
| 4 |
Javier P Gisbert, María Chaparro. Predictors of Primary Response to Biologic Treatment [Anti-TNF, Vedolizumab, and Ustekinumab] in Patients With Inflammatory Bowel Disease: From Basic Science to Clinical Practice. Journal of Crohn's and Colitis 2020; 14(5): 694 doi: 10.1093/ecco-jcc/jjz195
|
| 5 |
Tomas Kupka, Jarmila Simova, Jana Dvorackova, Lubomir Martinek, Oldrich Motyka, Magdalena Uvirova, Petr Dite. Crohn's disease - genetic factors and progress of the disease. Biomedical Papers 2018; 162(2): 139 doi: 10.5507/bp.2017.058
|
| 6 |
Beckley K. Davis, Casandra Philipson, Raquel Hontecillas, Kristin Eden, Josep Bassaganya-Riera, Irving C. Allen. Emerging Significance of NLRs in Inflammatory Bowel Disease. Inflammatory Bowel Diseases 2014; 20(12): 2412 doi: 10.1097/MIB.0000000000000151
|
| 7 |
Magali de Bruyn, Séverine Vermeire. NOD2 and bacterial recognition as therapeutic targets for Crohn’s disease. Expert Opinion on Therapeutic Targets 2017; 21(12): 1123 doi: 10.1080/14728222.2017.1397627
|
| 8 |
Youlian Zhou, Hanchang He, Pu Wang, Ting Zhang, Minyi Lin, Hong Wang, Yuqiang Nie, Ye Chen. Infliximab for the treatment of Crohn’s disease. European Journal of Gastroenterology & Hepatology 2015; 27(11): 1270 doi: 10.1097/MEG.0000000000000447
|
| 9 |
Javier P Gisbert, Alicia C Marín, María Chaparro. The Risk of Relapse after Anti-TNF Discontinuation in Inflammatory Bowel Disease: Systematic Review and Meta-Analysis. American Journal of Gastroenterology 2016; 111(5): 632 doi: 10.1038/ajg.2016.54
|
| 10 |
Konstantinos Papamichael, Niels Vande Casteele, Ann Gils, Sophie Tops, Scott Hauenstein, Sharat Singh, Fred Princen, Gert Van Assche, Paul Rutgeerts, Severine Vermeire, Marc Ferrante. Long-Term Outcome of Patients With Crohn’s Disease Who Discontinued Infliximab Therapy Upon Clinical Remission. Clinical Gastroenterology and Hepatology 2015; 13(6): 1103 doi: 10.1016/j.cgh.2014.11.026
|
| 11 |
Youlian Zhou, Zhenjiang Zech Xu, Yan He, Yunsheng Yang, Le Liu, Qianyun Lin, Yuqiang Nie, Mingsong Li, Fachao Zhi, Side Liu, Amnon Amir, Antonio González, Anupriya Tripathi, Minhu Chen, Gary D. Wu, Rob Knight, Hongwei Zhou, Ye Chen, Danilo Ercolini. Gut Microbiota Offers Universal Biomarkers across Ethnicity in Inflammatory Bowel Disease Diagnosis and Infliximab Response Prediction. mSystems 2018; 3(1) doi: 10.1128/mSystems.00188-17
|
| 12 |
Stefano Kayali, Stefano Fantasia, Federica Gaiani, Lucas Giovanni Cavallaro, Gian Luigi de’Angelis, Luigi Laghi.
NOD2 and Crohn’s Disease Clinical Practice: From Epidemiology to Diagnosis and Therapy, Rewired. Inflammatory Bowel Diseases 2024; doi: 10.1093/ibd/izae075
|
| 13 |
Boris Gole, Uroš Potočnik. Pre-Treatment Biomarkers of Anti-Tumour Necrosis Factor Therapy Response in Crohn’s Disease—A Systematic Review and Gene Ontology Analysis. Cells 2019; 8(6): 515 doi: 10.3390/cells8060515
|
| 14 |
Gan Shi, Li-Ping Li, Qi Zhao, Guan-Yi Wang, Bei Lei, Fang Liu, Guang-Rong Lu, Wen-Yao Shi, Xiao-Lin Li. Value of serum platelet/albumin and C-reactive protein/albumin ratios in evaluating mucosal healing and disease recurrence in patients with Crohn’s disease. World Chinese Journal of Digestology 2023; 31(14): 598 doi: 10.11569/wcjd.v31.i14.598
|
| 15 |
Bianca JC van den Bosch, Marieke JH Coenen. Pharmacogenetics of inflammatory bowel disease. Pharmacogenomics 2021; 22(1): 55 doi: 10.2217/pgs-2020-0095
|
| 16 |
Anita Annaházi, Tamás Molnár. Optimal Endpoint of Therapy in IBD: An Update on Factors Determining a Successful Drug Withdrawal. Gastroenterology Research and Practice 2015; 2015: 1 doi: 10.1155/2015/832395
|
| 17 |
Cong Dai, Yi-Nuo Wang, Wen-Ning Tian, Yu-Hong Huang, Min Jiang. Long-term clinical outcomes after the discontinuation of anti-TNF agents in patients with inflammatory bowel disease: a meta-analysis. Revista Española de Enfermedades Digestivas 2023; doi: 10.17235/reed.2023.9537/2023
|
| 18 |
Renske W.M. Pauwels, C. Janneke van der Woude, Daan Nieboer, Ewout W. Steyerberg, María J. Casanova, Javier P. Gisbert, Nick A. Kennedy, Charlie W. Lees, Edouard Louis, Tamás Molnár, Kata Szántó, Eduardo Leo, Steven Bots, Robert Downey, Milan Lukas, Wei C. Lin, Aurelien Amiot, Cathy Lu, Xavier Roblin, Klaudia Farkas, Jakob B. Seidelin, Marjolijn Duijvestein, Geert R. D’Haens, Annemarie C. de Vries, Annemarie C. de Vries, Renske W.M. Pauwels, C. Janneke van der Woude, Daan Nieboer, Ewout W. Steyerberg, Jasmijn A.M. Sleutjes, Marjolijn Duijvestein, Geert R. D’Haens, María J. Casanova, Javier P. Gisbert, Nick A. Kennedy, Charlie W. Lees, Edouard Louis, Tamás Molnár, Kata Szántó, Eduardo Leo, José M. García-Ortiz, Robert Downey, Alenka J. Brooks, Peter J. Hamlin, Shaji Sebastian, Alan J. Lobo, Milan Lukas, Wei C. Lin, Aurelien Amiot, Cathy Lu, Levinus (Leo) A. Dieleman, Xavier Roblin, Shomron Ben-Horin, Klaudia Farkas, Jakob B. Seidelin, Casper Steenholdt, Steven Bots. Prediction of Relapse After Anti–Tumor Necrosis Factor Cessation in Crohn’s Disease: Individual Participant Data Meta-analysis of 1317 Patients From 14 Studies. Clinical Gastroenterology and Hepatology 2022; 20(8): 1671 doi: 10.1016/j.cgh.2021.03.037
|
| 19 |
Glen Doherty, Konstantinos H Katsanos, Johan Burisch, Matthieu Allez, Konstantinos Papamichael, Andreas Stallmach, Ren Mao, Ingrid Prytz Berset, Javier P Gisbert, Shaji Sebastian, Jarosław Kierkuś, Loris Lopetuso, Edyta Szymanska, Edouard Louis. European Crohn’s and Colitis Organisation Topical Review on Treatment Withdrawal [‘Exit Strategies’] in Inflammatory Bowel Disease. Journal of Crohn's and Colitis 2018; 12(1): 17 doi: 10.1093/ecco-jcc/jjx101
|
| 20 |
J. P. Gisbert, A. C. Marín, M. Chaparro. Systematic review: factors associated with relapse of inflammatory bowel disease after discontinuation of anti‐TNF therapy. Alimentary Pharmacology & Therapeutics 2015; 42(4): 391 doi: 10.1111/apt.13276
|
| 21 |
Konstantinos Papamichael, Severine Vermeire. Withdrawal of anti-tumour necrosis factor α therapy in inflammatory bowel disease. World Journal of Gastroenterology 2015; 21(16): 4773-4778 doi: 10.3748/wjg.v21.i16.4773
|